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Abstract 
 
Background: HIV positive women have a greater risk of cancer of the cervix and 
they were also found to have high rates of prevalent and incident LSIL and HSIL. 
Both HIV and Cervical cancer are major public health problems in South Africa. This 
study will therefore assess whether HIV infected women with a LSIL on Pap smear 
have clinically significant cervical disease as determined by histology. 
 
Methods: HIV positive women with cytological abnormality on Pap smear are 
referred to colposcopy according to the SA guidelines.  When the colposcopy is more 
than CIN2 a LLETZ is performed. Data was extracted from a colposcopy database. 
 
Results: There were 652 patients and the mean age was 36.55 years and the 
median parity was 3.00. There were 266 women (40.80%) who had a histology result 
of HPV/CIN 1 and 386 women (59.20%) who had a histology result of CIN 2 or more 
severe lesion.  
 
Conclusion: Our study showed that most of the patients that were referred to our 
colposcopy clinic had CIN2 or more severe on histology and there were 5 women 
with invasive disease. The time from performing the Pap smear to colposcopy is 
extremely long. It is important that women with LSIL be referred to colposcopy as 
soon as possible.  
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CHAPTER 1 
 
1.1 Introduction 
Cervical cancer is the third leading cause of cancer in women in the world (1) and it is 
the leading cause of death by cancer in developing countries.(2-6) In South Africa 
(SA), the overall crude incidence rate of cervical cancer is estimated to be 19.64/100 
000.(7)   Women with Human Immunodeficiency Virus (HIV) have been shown to have 
a high risk of Human Papillomavirus (HPV) infection, which is known to be 
associated with almost all of cancers of the cervix.(2,4)  
 
Both HIV and cervical cancer are major public health problems in South Africa.(3) HIV 
positive women have a greater risk of cancer of the cervix.(3,5)  They were also found 
to have high rates of prevalent and incident Low Grade Squamous Intraepithelial 
Lesions (LSIL) and High Grade Squamous Intraepithelial Lesions (HSIL), with 
relatively low risk of regression to normal from LSIL.(5,8) The progression from low 
grade to high grade has been different in different populations. Two observational 
studies and one randomized controlled trial have shown that a progression from LSIL 
to HSIL in HIV positive women is 14% – 22%.(3,5) HIV positive women are also more 
prone to having detectable levels of HPV in cervical specimens than HIV negative 
women.(5) The prevalence of Squamous Intraepithelial Lesions (SIL) among HIV 
positive women has been estimated to be between 12% to 50%. Moodley J R, 
Hoffman M, Carrara H et al found a 50% prevalence of cytological abnormalities 
among HIV positive women in a study done in Cape Town.(3,5)  
 
Prevention of cervical cancer has been possible in developing countries because of 
effective screening and treatment of pre-cancer lesions.(3) The cervical cancer 
screening recommendation in developed countries is that HIV positive women should 
be screened more frequently than HIV negative women. It is recommended that HIV 
positive women have two Pap smears within the first year after HIV diagnosis and 
annually thereafter. Women would then be referred for colposcopy for any smear 
showing Atypical Cells of Undetermined Significance (ASCUS) or a more severe 
lesion.(3) The new guidelines in SA recommend that all HIV infected women be 
screened for cervical cancer precursors at diagnosis and then 3 yearly in those with a 
negative screening test.(9) HIV infected women with ASCUS and more severe are 
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referred to colposcopy.(10)  The problem facing South Africa is that both HIV and 
cervical cancer are common and resources are limited.(3)  Most HIV negative women 
with LSIL will have a normal Pap smear in 12 months without treatment.(11)  HIV 
positive women are less likely to clear the HPV.(12) Colposcopy may be difficult in 
women who have a high HPV load and who have warts covering the cervix and 
vagina. There are, however, no studies assessing the performance of colposcopy in 
HIV positive women. Referral of women with LSIL to colposcopy increases the 
workload at colposcopy clinic, and may lead to unnecessary treatment. An 
aggressive management protocol for HIV positive women with LSIL might do more 
harm than good. This study is therefore aimed at understanding LSIL in HIV infected 
women. 
   
1.2 HIV and Cervical Cancer in South Africa 
In South Africa (SA), current data on cervical cancer is lacking. This is due to failure 
of maintaining the pathology-based cancer registry. The last National Cancer 
Registry report was in 2004 in which 4636 new cases of cervical cancer were 
recorded, with a crude incidence rate of 19.64 per 100 000/year. Cancer of the cervix 
is the second commonest cancer among women in South Africa.(7)   According to the 
Globocan 2012 report, the extrapolated incidence of cervical cancer in South Africa 
was 7735 cases.(13) Cervical cancer was included as one of the Acquired Immune 
Deficiency Syndrome (AIDS) defining illnesses in 1993.(3,5)   
 
The burden of HIV in Sub-Saharan Africa is high.(14) South Africa has a high burden 
of HIV and women are more affected than men.  Young women have a two-fold HIV 
seroprevalance rate than men.(10)  The estimated prevalence of HIV infection among 
Gauteng antenatal attendees was 29.9% in 2012 (14) 
 
Immune deficiency in HIV is associated with a rapid progression of premalignant 
lesions and a slower regression. A study done by Six C, Heard I, Bergeron C et al 
showed that LSIL progressed to HSIL in 38.1% of HIV positive women with a CD4 
count less than 500 cells/mm3 in a period of one year and there was no progression if 
the CD4 was more than 500 cells/mm3.(15) High rates of prevalent SIL in HIV positive 
women at a relatively young age have been reported. A cross sectional study done in 
Johannesburg by Finhaber showed an increasing risk of cervical lesions with a 
3 
 
decreasing CD4 count.(16) A prevalence of cervical cancer among HIV positive 
patients has been shown to be nearly double that of HIV negative patients.(3,17)  HIV 
positive patients present with cervical cancer nearly 10 years earlier than HIV 
negative patients. Additionally, if their CD4 count is less than 200 cells/mm3 at 
presentation they are significantly more likely to have advanced stage of cervical 
cancer.(17)  
 
1.3 Natural History of cervical cancer 
Persistence of high-risk HPV infection has been shown to be an important 
association with cervical cancer.(18,19)  HPV is one of the most common sexually 
transmitted infections in the world. It has been suggested that most sexually active 
individuals have been infected with HPV at least once in their lifetime.(20,18) The 
infection with HPV is usually transient and most individuals clear the virus without 
any clinical manifestation.(20)  
 
HPV infects the developing immature metaplastic cells of the transformation zone of 
the cervix.(19)  The virus targets the basal cells and these act as reservoirs of the 
virus once infected.(21) Premalignant and malignant cells arise as a result of HPV 
DNA integration into the host cellular genome with a resultant overexpression of the 
viral E6 and E7 oncogenes. Cells acquire a proliferative advantage by escaping 
growth control exerted by p53 and p105Rb which are inactivated by E6 and E7 
proteins respectively.(19) Persistence of infection can lead to cervical cancer 
precursors which can be low-grade and high-grade squamous intra-epithelial lesions 
(SIL), subsequently leading to cervical cancer.(21) 
 
There are more than 40 HPV types that have been associated with mucosal infection 
of the anogenital tract and these have been classified according to their oncogenic 
potential as either low- or high-risk HPV types. The low-risk HPV types cause benign 
hyperproliferative lesions/genital warts, and these are usually HPV 6 and 11 and less 
commonly 40, 42, 43, 44, 54, 61, 72, 73, and 81. The high-risk oncogenic HPV types 
are strongly associated with premalignant and malignant cervical lesions and these 
are usually HPV 16, 18, 45 and 31 and less commonly 33, 35, 39, 51, 52, 56, 58, 59, 
68, 69, 73 and 82.(20)  
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Cervical intraepithelial neoplasia (CIN) is assumed to progress through a long 
preinvasive state before developing into invasive cancer.(23)  Squamous cervical 
cancer is initiated by infection with the HPV and generally progresses in stages from 
LSIL to HSIL and HSIL may result in invasive cancer of the cervix.(19) Screening 
programmes have allowed for the detection of the preinvasive lesions which can be 
effectively treated.  Previous studies have shown that a number of LSIL will 
spontaneously regress.(23) A meta-analysis representing 27 929 patients found that 
the rate of regression to normal was 68% for women with ASCUS and 48% for LSIL 
and 35% for HSIL. (23)   The rate of progression to HSIL at 24 months was 7% for 
ASCUS and 21% for LSIL.(23) The rate of progression to cervical cancer at 24 months 
was 0.25% for ASCUS, 0.15% for LSIL and 1.44% for HSIL. (23)   A comprehensive 
review and a cohort study of 17 000 women have suggested that the majority of LSIL 
will regress within 2 years. (23)  Bansal N, Wright J D and Cohen C J et al also 
confirmed these findings which showed that 52% of CIN 1 patients regressed within 1 
year while 10% progressed to high grade disease.(23)  On the other hand, McCredie, 
Sharples KJ, Paul C et al showed that the incidence of progression of CIN 3 to 
invasive cancer of the cervix at 30 years was 31.3% in women that were not treated 
for CIN 3.(19)   
 
The prevalence of LSIL has been reported to be between 1.6 – 2.4% in population-
based surveys.(10)  A number of studies have found the prevalence of squamous 
intraepithelial lesions among HIV-positive women to be 31% to 63%.(24, 25-27) 
Progression of LSIL was associated with lower CD4 counts and presence of HPV 
types 16, 18, and 33.(5) Furthermore, the prevalence and degree of dysplasia 
increases with advancing levels of immunosuppression.(24) 
 
Gaym A, Mashego M and Kharsany A B F et al. showed that LSIL was the most 
common abnormality identified on Pap smears of HIV positive women. The 
prevalence of LSIL was 9.2% and the prevalence of HSIL was 1.3% in this group of 
women. (24)  They also showed that there was a statistically significant association 
between HIV infection and abnormal Pap findings. They found that abnormal Pap 
smears occurred in 36% of HIV-positive women as compared to 10.3% of HIV-
negative women.(24) African studies have shown a  higher prevalence of 38% of HIV 
positive women having premalignant cervical lesions at first Pap smear. Omar T, 
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Schwartz S, Hanrahan C et al study showed that 21.5% of women with a baseline of 
LSIL progressed to HSIL at 5.5 months follow-up. (10)  Progression was associated 
with a low CD4 count.  Women having CD4 counts less than 200 cells/mm3 had a 
two-fold increased risk of progression from LSIL to HSIL.(10)  
 
1.4 Risk Factors for HPV Infection 
Risk factors for HPV infection include early age of coitarche and number of sexual 
partners.(4) Other risk factors include history of other HPV-mediated neoplasia, 
immunosuppression, prior sexually transmitted infection, low socioeconomic status 
and history of smoking. Use of oral contraceptive pills (OCP) increases the risk of 
cervical cancer in women infected with HPV, but there is no evidence that OCPs 
increase the risk of HPV infection.(4)  
 
1.5 Screening for cervical cancer 
Cervical cancer screening programmes are aimed at reducing mortality and morbidity 
resulting from cervical cancer. The existence of premalignant lesions of the cervix 
can be detected through screening and these lesions can subsequently be managed 
accordingly.(8)  Early treatment options of premalignant lesions are effective in 
preventing cervical cancer.(4)  
 
Methods used for cervical cancer screening include Pap smear, visual inspection 
with 5% acetic acid and Human Papillomavirus detection.(28) Pap smear is 
recognized as an effective, successful and well accepted test for cervical cancer 
screening.(2) Furthermore, certain high risk HPV types associated with cervical 
cancer have been identified. There are different tests available for detecting high risk 
HPV DNA and these tests can be used for both screening and diagnosis.(8)   These 
HPV tests, however, are not available in public hospitals due to high costs.(21)  
 
Sankaranarayanan R, Nene BM, Dinshaw KA et al conducted a randomized cervical 
cancer screening trial in 52 villages in India, with a total of 142 701 healthy women 
between the ages of 30 and 59 years. (22) The groups were randomized to undertake 
screening by HPV testing, cytological testing, visual inspection with acetic acid (VIA), 
or standard of care (no screening). Women with positive screening tests were 
referred for colposcopy and biopsy and for treatment if lesions were detected. The 
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hazard ratios for the incidence of advanced cancer and death in the HPV testing 
groups were 0.47 (95% CI: 0.32 – 0.69) and 0.52 (95% CI: 0.32 – 0.83) respectively, 
as compared with the control group. There were no significant reductions in the 
numbers of advanced cancers or deaths observed in the cytological testing and the 
VIA group compared with the control group. This study showed that alternative 
strategies to cytology are effective in identifying premalignant lesions and therefore 
reducing the incidence of cervical cancer. The problem with HPV DNA testing is that 
it is extremely expensive.(22) 
 
1.6 Colposcopy 
Colposcopy may be used as a screening tool in some areas and it is also used as a 
diagnostic aid.(29)  In most clinics in SA and at the colposcopy clinic at CHBAH,  
colposcopy is used for diagnosis and to plan a punch biopsy or to decide on 
treatment with Large Loop Excision of the Transformation Zone (LLETZ).  
Colposcopy has a sensitivity of 91.3% and a specificity of 24.6% in a meta-analysis 
conducted by Underwood M, Arbyn M, Parry-Smith W et al.(30) Using scoring systems 
like the Reid score and the Swede score may assist in making colposcopy more 
accurate.(31) 
 
The Reid score is a systematic and objective colposcopic method of grading the 
severity of premalignant cervical lesions. The index considers four attributes of 
premalignant cervical lesions. The first colposcopic sign considers the colour 
(intensity) of aceto-whitening, the second sign considers the nature of the lesion 
margin and surface contour of acetowhite areas, the third sign considers vascular 
changes or features and the fourth considers the colour changes after iodine 
application. The first three signs are evaluated following application of 3-5% acetic 
acid to the cervix. The last sign is dependent on a preliminary score of the first three 
signs and is determined after Lugol‟s iodine application to the cervix.(32) Common 
cervical findings on colposcopy include acetowhite changes, punctations, mosaicism 
and abnormal vessels in women with CIN.(4) 
 
The Swede score is a scoring system developed by Strander B, Ellstrom-Andersson 
A Franzen S et al for colposcopic examination that uses five variables. These 
variables include acetowhiteness, margins and surface, vessels, lesion size and 
iodine staining. Each variable gets assigned a score of 0, 1 or 2 to predict a high 
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grade lesion on histology after a cone or biopsy. The possible total score is 0-10 and 
a score of ≥5 points showed HSIL and a score of ≥8 had a specificity of 90%.(33) This 
system is also used to identify patients with low grade lesions or normal findings and 
in their study, Strander B, Ellstrom-Andersson A, Franzen S et al showed that 17% of 
patients only needed to be followed up with colposcopy or cytology instead of 
biopsy.(33) 
 
1.7 Management of cervical pre-cancer Lesions 
Treatment of CIN is indicated in women with CIN2 and CIN3. The treatment of 
cervical squamous intraepithelial neoplasia is the removal or ablation of the 
transformation zone (TZ). Destructive methods of the TZ include cryotherapy, 
coagulation and laser ablation, while excisional methods include cold knife cone 
biopsy, laser excision, Large Loop Excision of the Transformation Zone (LLETZ) and 
hysterectomy.(29,34) 
 
Colposcopy is not a reliable method for recognising glandular disease or 
microinvasive cancer. Histology obtained by a LLETZ procedure has revealed 
between 0.6% and 1% of colposcopically unsuspected microinvasive disease. (29) 
According to Cantor SB, Cardenas-Turanzas M, Cox DD et al, colposcopy had a 
sensitivity of 0.983 and a specificity of 0.451 in the detection of LSIL when using a 
disease threshold of HSIL. They also found a sensitivity of 0.714 and a specificity of 
0.813 for the detection of HSIL.(35)   
 
The choice of method for the treatment of CIN is based on the size of the lesion, the 
age of the patient, HIV status, the patient‟s desire for future pregnancy and other 
gynaecological problems.(29,34) Hysterectomy is indicated in women with other 
gynaecological problems and when future pregnancy is not desired. Ablative 
methods are useful for women who wish to retain their fertility, but these methods 
have limitations in that they require histological diagnosis and they cannot be 
performed in women with a very atrophic cervix and where the lesion involves more 
than 2 quadrants of the cervix. (36)  Other excisional methods like LLETZ and cold 
knife cone may be used in women who wish to retain their fertility.(36)   
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Excision using a wire loop was first described by Cartier, in 1981, and he used this as 
a means of biopsy. (39)  The process has evolved to loops which are larger and with 
different shapes and sizes thus allowing tailoring of treatment based on colposcopic 
diagnosis. This procedure is performed under local anaesthesia, is easy to perform 
and has proven to be acceptable to patients and is available in many hospitals.(37)  
 
Two large meta-analytical reviews were done to look at the relative obstetric risks 
associated with excisional methods of cervical biopsy.(29,38) The review by Kyrgiou M, 
Koliopoulos G, Martin-Hirsch P et al studied preterm pregnancy-related outcomes in 
women who subsequently conceived after being treated for CIN by cold knife cone 
biopsy, laser ablation, laser cone and LLETZ. The review showed an increased risk 
for preterm labour (Relative Risk, RR 1.7) in women who had been treated by LLETZ 
compared to women who had not had treatment.  Similarly there was an increased 
risk for low birth weight and premature rupture of membranes.(29,38)  There was a 
marginally non-significant association between laser conisation and preterm delivery 
(RR 1.71).(38) Laser ablation was not associated with any obstetric complications 
mentioned above. Cold knife cone, however was associated with a significant 
increase in low birth weight (RR 2.53), preterm delivery (RR 2.59) and caesarean 
section (RR 3.17).(38)  
 
It has also been shown in the literature that the risk of preterm birth increased with a 
greater depth of excision of the cervix. In a case control study done by Castanon A, 
Landy R, Brocklehurst P et al, there was a 15.3% risk of preterm birth in women who 
had large excisions of ≥15 mm and there was a 7.2% risk in patients with a punch 
biopsy or excisions ≤10 mm compared with a 6.7% risk in the general population.(37) 
Short term complications of excisional biopsy included incomplete excision, which 
can lead to the increased risk of the residual disease being present in the 
subsequent follow up of the patient.(29)   
1.7.1 Management Options for LSIL 
Prevention of cervical cancer relies on the detection of cervical cancer precursors 
and this is performed using the Pap smear in SA. There are 3 management options 
for patients with LSIL on a Pap smear: refer to colposcopy; do an HPV test or repeat 
the Pap smear. Women with abnormal smears are referred for colposcopy and in 
some clinics the diagnosis is confirmed with a punch biopsy after which treatment 
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occurs.(21) In SA and in many other developing countries diagnosis is combined with 
treatment where immediate treatment with excision of the TZ is performed at the first 
colposcopic visit. This protocol is used to minimize loss to follow-up and to avoid long 
waiting periods due to poor infrastructure and scarce resources.(39) The specimen is 
then sent for histology after excision and this gives the final diagnosis.  Treatment 
with ablative technologies needs to be based on the histological specimen.(7) 
 
In view of the increased risk of cervical disease among HIV positive women, the 
Center for Disease Control (CDC) recommended that all HIV positive women should 
have a Pap smear performed as part of their initial evaluation when diagnosed with 
HIV. If the Pap smear should be found to be negative, the smear should be repeated 
in six months. Women who have had at least two negative Pap smears and never 
had an abnormal smear can have a Pap smear performed every 12 months.(5)  The  
guidelines in SA recommend that all HIV infected women be screened for cervical 
cancer precursors at diagnosis and then 3 yearly in those with a negative screening 
test.(9) HIV infected women with an ASCUS and more severe are referred to 
colposcopy.(10)   
 
Results from a few observational studies and one clinical trial suggested that 
observation without excisional therapy was appropriate management for HIV positive 
women with LGSIL or CIN 1. However, LLETZ has been recommended as the 
preferred method of treatment should treatment be required.(5)  LLETZ may be used 
for excising the TZ as a simple outpatient procedure under local anesthetic 
infiltration, enabling comprehensive histological evaluation of the entire specimen. 
This therefore enables a true diagnosis, establishment of the excision margins and 
possibility of microinvasive or glandular disease.(32) 
  
1.8 Problem statement and justification 
Most cervical cancer guidelines, including the South African guidelines, recommend 
that HIV positive women with any cytological abnormality of ASCUS and more severe 
get referred to colposcopy.(7,9) Studies have confirmed the high HPV prevalence in 
HIV infected women. (7,9)  The prevalence of LSIL is therefore also high. It is however 
not clear how many of these women with LSIL are just HPV infection or dysplasia. 
Such information may assist in the management of HIV infected women with a LSIL 
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on their Pap smear and this information will add to our existing knowledge on the 
subject. 
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1.9 Study objectives 
1. To describe characteristics of HIV infected women with LSIL on Pap smear. 
2. To compare women with CIN 1 on histology with those who have CIN 2/CIN3 
on histology. 
3. To compare the colposcopy findings to the histology results  
4. To describe the proportion of women who have been overcalled at colposcopy 
and the proportion of women who were undercalled at colposcopy.  
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CHAPTER 2 
 
2.1 Methodology 
2.1.1 Study Design  
This study is a cross sectional analysis of data from the colposcopy clinic database at 
Chris Hani Baragwanath Academic Hospital (CHBAH) from April 2003 to Dec 2013. 
The data was prospectively entered into the colposcopy database as patients were 
seen at the colposcopy clinic.  
2.1.2 Variables that are recorded in the database  
Information on the demographic details including age and parity, HIV status, CD4 
count, ART use, current contraceptive use, smoking, snuff usage, cervical cytology 
results, colposcopy findings and histology was recorded in the database. Cervical 
cytology was performed using the conventional Papanicolaou smear and reported 
using the Bethesda Classification. Colposcopy at CHBAH was done by consultants 
or registrars under consultant supervision. Finesse I® and Finesse II® colposcopic 
machines were used in the colposcopy clinic and relevant sizes of the UtahLoop® or 
C-LETZ® were used to perform the LLETZ.  Colposcopic diagnoses were made using 
the Modified Reid Score (Appendix F).  
 
2.1.3 Study Setting/Population 
Chris Hani Baragwanath Academic Hospital is a tertiary hospital situated in a large 
urban township called Soweto. The population of Soweto is comprised of economic 
migrants from rural South Africa and neighbouring African countries as well as 
political refugees from neighbouring African countries.  The township mainly 
comprises black South Africans from different economic and educational 
backgrounds.  
 
The CHBAH colposcopy clinic is a referral centre for Soweto and the Southern parts 
of Gauteng Province. According to the SA guidelines, HIV positive women with any 
cytological abnormality on Pap smear should be referred to colposcopy.(9)  HIV 
positive women with LSIL on Pap smear were referred to Chris Hani Baragwanath 
Academic Hospital Gynaecology Outpatients according to referral guidelines (Fig 1).   
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HIV positive women with cervical cytology showing LSIL or more and colposcopy of 
CIN1 were treated immediately prior to 2008 because of the concern that CIN1 would 
progress more rapidly in HIV infected women.  After 2008, a LLETZ was performed 
immediately in women where the colposcopy was equal to or more than CIN2 or if 
the colposcopy was inadequate or if the cervix was covered with warts.  
 
Figure 2.1 Flow diagram showing the management of patients at CHBAH colposcopy clinic 
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2.2 Data management 
On the 8th April 2014, the data was extracted from the database. All relevant 
variables were entered into an Excel spreadsheet and subsequently coded for 
analysis. Duplicate records, HIV negative patients and patients with Pap smears that 
were not LSIL were thereafter excluded from the analysis. The next steps involved 
rechecking the missing data on the NHLS system and on the CHBAH record 
database for accuracy. The data was exported to a statistical programme and data 
analysis was performed using STATA statistical software (version 11). 
After 2006, all women who did not know their HIV status, or who have tested 
negative more than 6 months prior to their first colposcopy at visit CHBAH were 
offered an HIV test (Personal communication). Patients that came to the clinic with 
an unknown HIV status at first visit were considered HIV positive at that time if they 
tested HIV positive within 6 months of the first colposcopy visit. 
 
The following variables were extracted from the database: Age, HIV status, CD4 
count, ART use, parity, contraceptive use, smoking, use of snuff, Pap smear results, 
colposcopic diagnosis and histology, dates of Pap smear and dates of colposcopy. 
Two new variables were created using the histology result: HPV or CIN1 (as a proxy 
for overtreatment) and CIN2 and more severe (as a proxy for appropriate treatment).  
 
At Chris Hani Baragwanath Academic Hospital (CHBAH), colposcopy with or without 
LLETZ is performed by specialist gynaecologists or by supervised registrars. 
Colposcopic diagnosis is performed using a method based on the Modified Reid 
Colposcopic Index. All pap smears were performed using the conventional method. 
Most Pap smears were performed by the National Health Laboratory Services 
(NHLS) and some of the women had their Pap smears done by private laboratories. 
All histological examinations were performed and processed by the NHLS which has 
a strict internal and external quality control.  
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2.3 Data analysis 
2.3.1 Descriptive and Analytical Statistics  
All categorical variables are described using frequencies and percentages. 
Continuous variables are described using means and standard deviation (SD) and/or 
medians with IQRs. A new outcome variable was created: HPV/CIN1 and CIN2 and 
more severe. CIN2 was used as a cut-off because this is the threshold for treatment 
at this clinic. 
 
Comparisons were made using the Chi square test for categorical variables and the 
Student T-test or Wilcoxon rank for comparing continuous variables. A logistic 
regression analysis was used to find the strength of associations. A p-value of <0.05 
is considered significant.  
 
2.4 Ethics 
All women at the colposcopy clinic were counseled and requested to sign an 
informed consent form that allowed their data to be used for audit, follow-up and 
research (Ethics clearance certificate for the Database – M080603/M040609). The 
ethics application was updated and the certificate is attached (Appendix A). Women 
that declined to give consent were treated the same way as all other patients. 
 
Ethics approval to do this study was obtained from the Human Research Ethics 
Committee of the University of the Witwatersrand, Clearance certificate number: 
M140220 (Appendix B). Approval to conduct the study was also obtained from the 
CEO at Chris Hani Baragwanath Hospital (Appendix C) and database gate keepers 
for NHLS for the use of Pap smear and Histology results (Appendix D). Permission 
was obtained from Dr Y Adam, Prof CJ van Gelderen, Dr F Kabir, Dr K Kgomo and 
Dr A Lekha for use of information from the colposcopy database (Appendix E). 
 
2.5 Funding 
Stationery was funded by the researcher. 
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CHAPTER 3 
 
3.1 Results 
The initial section of this chapter describes the study population including 
demographic information and HIV factors. The subsequent sections present 
other Pap smear, colposcopy and histology findings. This is followed by 
conducting a comparison between women with a histology result of CIN 1/HPV 
to women with CIN2 and more severe lesions. The chapter concludes by 
conducting an analysis of overtreatment and under treatment of women with 
LSIL. 
3.1.1 Study population 
There were a total of 6159 women on the colposcopy clinic database. Of the 6159 
women, 3895 (63.24%) were HIV positive women referred to CHBAH colposcopy 
clinic between 1st April 2003 and 31st December 2013. Of these, 660 women were 
referred with LSIL. Eight (8) women were excluded from the study as they did not 
have histology results.  The resultant 652 women formed part of the analysis. Of the 
652 women, 75 had a recurrent LSIL. The flow diagram below illustrates the above-
mentioned sample criteria.    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Flow diagram showing inclusion and exclusion criteria of study population 
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Age and parity 
The median age was 36.00 years (IQR= 31.00-42.00) with a range of 18.00 to 66.00 
years and a mean of 36.55 (SD± 7.68). The median parity was 3 (IQR= 2-5) and the 
mean was 3.22 (SD± 1.75) with a range of 0 to 10.  
 
Contraception 
As illustrated in figure 3.2 below, the largest proportion of women (n=285; 43.71%) 
only used condoms as a method of contraception. A significant number of women 
(n=152; 23%) were not using any form of contraceptive method, however, this may 
be explained by the fact that some of the women were either not in their reproductive 
years or not sexually active.   
 
 
 
Figure 3.2 Method of contraception at the time of presentation 
*Dual method indicates the use of condoms together with any hormonal contraceptive method 
** POP users (n=1) 
 
Cigarette Smoking 
Of the entire database, only 87 women‟s smoking records were recorded. This was 
because smoking was only captured from 2010 in the database. From the sample of 
87 women, 5 women (5.75 %) were recorded as smokers. Figure 3.3 below is a clear 
illustration of the proportion of smokers to non-smokers.  
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Figure 3.3 Proportion of women smoking cigarette  
 
Snuff Users 
Only 87 snuff usage information was recorded in the database. This information was 
only being recorded from the year 2010. From the sample of 87 women, 14 women 
(16.09%) were recorded as snuff users. Figure 3.4 below indicates the proportion of 
snuff users to non-users.  
 
 
 
Figure 3.4 Proportion of women using snuff 
 
 
 
 
  
82 
5 n= 87 
Non-Smoker (94.25%)
Smoker (5.75%)
73 
14 
n= 87 
Snuff non-users (83.91%)
Snuff users (16.09%)
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3.1.2 HIV factors  
 
HIV Duration 
The duration of HIV infection was only recorded after 2010 and was only known in 58 
women. The median interval between HIV diagnosis and the first colposcopy visit 
was 50.32 months (IQR= 24.6 – 104.2) and the range was between 12 days to a 
maximum of 212 months. The mean interval recorded was 63.05 months (SD± 48.2). 
 
CD4 count 
The CD4 count was known in 584 out of 652 women. At the point of first visit, the 
median CD4 count recorded was 275.00 cells/mm3 (IQR = 173.50 – 434.00) and the 
mean was 321.00 cells/mm3 (SD± 217.25). The number of women with a CD4 count 
less than or equal to 200 cells/mm3 was 190 (32.53%); women with a CD4 count 
above 200 cells/µL and below 350 cells/mm3 was 180 (30.82%) and 214 women 
(36.64%) had a CD4 count above 350 cells/mm3.  
 
ART usage 
There were 312 women (47.85 %) using ART and 74 (11.35%) women had been 
exposed to ART as a prevention of mother to child transmission (PMTCT) before 
their colposcopy clinic visit, however, they were not using ART for their own health.  
A further 200 women (30.67%) had never used ART and 66 women (10.12%) had no 
ART information recorded in the database.  Figure 3.5 below demonstrates the 
various ART treatment findings.  
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Figure 3.5 ART usage 
 
3.1.3 Pap smear Findings 
 
Time Interval between the Pap smear and Colposcopy Assessments 
The median time between the Pap smear being performed and the initial colposcopy 
visit was 210.00 days (IQR= 132.00 - 313.00). The minimum time interval reported 
was 8.00 days and the maximum reported time interval was 2134.00 day 
(approximately 5 years and 10 months). The mean time interval was 239.19 with a 
standard deviation of ±183.62.  
 
Pap smear Report Findings 
There were 99 women (15.18%) that had other findings on their Pap smear results. 
Bacterial Vaginosis was found in 78 women (11.96%), 15 women (2.30%) had 
Candidiasis and 6 women (0.92%) had Trichomonas on their Pap smear results. 
Figure 3.6 below illustrates the proportion of women who had these findings.  
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Figure 3.6 Other findings on the Pap smear report 
 
3.1.4 Colposcopic and Histology Findings 
 
Colposcopic Report Findings 
The colposcopic diagnosis was not recorded in 28 women (4.29%) and a diagnosis 
could not be made in 31 women (4.75%). The most common colposcopic diagnosis 
was CIN2 as reflected in figure 3.7. 
 
 
Figure 3.7 Colposcopic diagnoses in women with LSIL on Pap smear 
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Methods used for obtaining Histology specimens 
Histology in this study was obtained by Punch biopsy, Loop excision (of the 
transformation zone), cold knife cone and hysterectomy as illustrated in table 3.1 
below. 
 
Hysterectomy, which is generally not a common method used for the management of 
premalignant lesions, was performed on 6 women (0.92%). The factors contributing 
to the hysterectomy being performed were as a result of a large lesion, the inability to 
see the cervix and inability to perform a loop and other concomitant gynaecological 
conditions requiring hysterectomy. 
 
LLETZ was performed either under local anaesthesia or under general anaesthesia. 
In the study population, 7 women had LLETZ performed under general anaesthesia, 
whereas 569 women had LLETZ performed under local anaesthesia. The reasons for 
LLETZ being performed under general anaesthesia are attributable to either inability 
to insert the speculum due to pain and/or severe discomfort; difficulty visualizing the 
cervix; a large lesion or the patient requesting general anaesthesia. 
 
Table 3.1 Cervical biopsy methods 
Method Frequency Percentage (%) 
LLETZ  (local anaesthesia) 569 87.27 
LLETZ  (general anaesthesia) 7 1.07 
Loop Biopsy  (local anaesthesia) 11 1.69 
Cone Biopsy 2 0.31 
Punch Biopsy 9 1.39 
Hysterectomy 6 0.92 
Not recorded 48 7.36 
Total 652 100.00 
 
Histology 
There were 266 women (40.80%) who had an histology result of HPV/CIN 1 and 386 
women (59.20%) had an histology result of CIN 2 or more severe lesion. Figure 3.8 
displays the breakdown of different histological categories. There were no histology 
reports that were normal. 
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Figure 3.8 Histology results 
 
 
Histology of invasive disease 
There were 5 women with histology of invasive disease. The staging of these 
cancers are not recorded in the database as these women are referred for 
oncological assessment and treatment. Table 3.2 below describes these women. The 
mean age of women with invasive cervical cancer was 27.2 years (SD± 8.84), mean 
parity was 3.4 (SD± 1.52), mean CD4 count was 333.00 cells/mm3 (SD± 165.70) and 
the mean time to colposcopy was 229.4 days (SD±131.27). 
 
Table 3.2 Characteristics of women with invasive disease 
 Parity Time from Pap 
to 1st visit 
CD4 
(cells/mm3) 
Age Use of ART 
Patient 1 1 436 175 45 No ART 
Patient 2 3 155 403 44 ART 
Patient 3 1 208 unknown 54 No ART 
Patient 4 2 90 534 30 No ART 
Patient 5 3 258 223 49 No ART 
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3.1.5 Comparison between Colposcopic Diagnosis and Histology Results 
 
A total of 591 women had histology results as well as a colposcopic diagnosis. The 
histology results were compared to the colposcopic findings. The analysis in table 3.2 
below is a summary of the relationship between findings from each procedure. There 
were no histology reports that were normal. Each diagnosis is explained in the text 
that follows the table. 
 
 
Table 3.3 Comparison of colposcopy diagnosis with histology results 
Colposcopy  CIN1 CIN2 CIN3 Micro-
invasion 
Invasion Normal Total 
Histology  
HPV 3.00 
(1.83%) 
3.00 
(0.92%) 
1.00 
(1.23%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
7.00 
 
CIN1 99.00 
(60.37%) 
113.00 
(34.56%) 
11.00 
(13.58%) 
1.00 
(20.00%) 
0.00 
(0.00%) 
5.00 
(55.56%) 
229.00 
 
CIN 2 41.00 
(25.00%) 
134.00 
(40.98%) 
43.00 
(53.09%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
1.00 
(11.11%) 
219.00 
CIN 3 21.00 
(12.80%) 
76.00 
(23.24%) 
26.00 
(32.10%) 
3.00 
(60.00%) 
2.00 
(40.00%) 
3.00 
(33.33%) 
131.00 
Microinvasion 0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
Invasion 0.00 
(0.00%) 
1.00 
(0.31%) 
0.00 
(0.00%) 
1.00 
(20.00%) 
3.00 
(60.00%) 
0.00 
(0.00%) 
5.00 
Normal 0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
(0.00%) 
0.00 
Total 164.00 
 
327.00 81.00 5.00 5.00 9.00 591.00 
 
 
Colposcopy diagnosis of CIN1- compared to histology findings 
Of the 164 women that were diagnosed with CIN1 on colposcopy, 99 women 
(60.37%) were diagnosed with CIN1 on histology. On the other hand, 41 women 
(25.00%) were diagnosed with CIN2 and 21 women (12.80%) with CIN3 on histology. 
This represents a total of 62 women (37.00%) who were underdiagnosed at   
colposcopy. A further 3 women (1.83%) who had CIN1 on colposcopy only had HPV 
diagnosis on histology.  
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Colposcopy diagnosis of CIN2 – compared to histology findings 
Out of the 327 women who were diagnosed as CIN2 at colposcopy, 113 (34.56%) 
had CIN 1 and 3 women (0.92%) had HPV on histology. This represents a total of 
116 (35.48%) women who were over-diagnosed based on their colposcopy findings 
in comparison to their histology findings. Conversely, 76 women (23.24%) had CIN 3 
and 1 woman (0.31%) had invasion on histology, indicating that a total of 77 women 
(23.55%) were underdiagnosed at colposcopy. There was absolute correlation in 134 
women (40.98%), who were therefore correctly diagnosed.  
 
Colposcopy diagnosis of CIN3 – compared to histology findings 
There were 81women that had CIN 3 at colposcopy. Out of the 81 women, 1 woman 
(1.23%) had HPV, 11 women (13.58%) had CIN 1 and 43 women (53.09%) had CIN 
2 on histology, hence 55 women (67.90%) were over-diagnosed at colposcopy. 
Twenty-six women (32.10%) had CIN 3 diagnosis on both procedures, which 
demonstrates a low proportion of accuracy of colposcopy for a diagnosis of CIN3 in 
women with a LSIL on Pap smear. In this category, no patients were underdiagnosed 
at colposcopy.  
  
Colposcopic diagnosis of ≥CIN2 combined  
CIN 2 and more severe is the threshold above which a LLETZ is performed at this 
clinic. There were 418 women in this group who were diagnosed with CIN 2 and 
more severe. Of these 289 (69.14%) would have been appropriately treated.  
 
Colposcopic Diagnosis of Microinvasion – compared to histology findings 
There were 5 women that were diagnosed as microinvasion at colposcopy. Out of 
these 5 women, 1 woman (20.00%) had CIN 1 and 3 women (60.00%) had CIN3 on 
histology, respectively – indicating 80% patient over-diagnosis at colposcopy. The 
remaining women (20.00%) had a histology diagnosis of invasion, reflecting 
underdiagnosis at colposcopy. There was no accurate diagnosis of microinvasion 
using colposcopy.  
 
Colposcopic Diagnosis of Invasion – compared with histology findings 
There were 5 women that had invasion as a diagnosis at colposcopy. Out of the 5 
women, 2 women (40%) had CIN 3 on histology, reflecting the number of women that 
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were over-diagnosed at colposcopy. However, 3 of the 5 women (60%) were 
accurately diagnosed at colposcopy as invasion as this was confirmed histologically. 
 
‘Normal’ Colposcopy finding – compared with histology findings 
There were 9 women that had a normal colposcopy. Out of the 9 women, 5 women 
(55.56%) had CIN 1 on histology, 1 woman (11.11%) had CIN 2 on histology and 3 
women (33.33%) had CIN 3 on histology. All women (100%) in this category were 
under diagnosed as none of the histology results were normal. 
 
3.1.6 Margins 
 
Over 50% of women had clear margins, 4.98% of women had involvement of both 
margins and 5.31% had involvement of the endocervical margins. Involvement of 
margins is shown in table 3.4 below. 
 
Table 3.4 Margins involved 
Margins Frequency Percentage (%) 
Both 31 5.15 
Ectocervical 203 33.72 
Endocervical 33 5.48 
Margins clear 321 53.32 
Unknown 14 2.36 
Total 602 100.00 
 
3.1.7 Comparison of women with CIN 1 with those who have CIN2 or more on 
histology 
Table 3.5 below is a comparison of factors according to demographic details in 
relation to severity of disease. The table displays the statistical difference between 
the women who had CIN1/HPV and the women who had CIN2 or more severe on 
histology. There were too few women where smoking and snuff were recorded. Due 
to the minimal sample size of smoking and use of snuff, there was no statistical 
difference of snuff use or smoking in the 2 histology categories hence it has not been 
represented in the table. 
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Table 3.5 Demographic details in relation to severity of disease 
 HPV/CIN1 
n=266 (40.80%) 
≥CIN2 
n= 386 (59.20%) 
p-value 
Mean Age 
36.55 (SD±7.68) 
37.14 (SD± 7.97) 36.15  (SD± 7.45) 0.00  (t-test) 
Mean Time from Pap to 
Colposcopy (days) 
266.73 (SD± 232.89) 220.69  (SD± 138.48) 0.00 (t-test) 
Use of ART 
N=312 (47.93%) 
n=149/266 (56.02%) n=163/386 (42.34%) 0.00 (chi2) 
Mean HIV duration in days 
(years) – only known in 58 
patients 
2105.70 (1527.95) 
 
(5.77 years) 
1586.38 (1322.77) 
 
(4.35 years) 
0.00 (t-test) 
Use of condoms 
(comparator) 
N=285 (71.43%) 
n=131/266 (SD± 
79.39) 
n=154/386 (SD± 
65.81) 
0.00 
Use of *any hormonal 
contraception 
N=114 (28.57%) 
n=34/266 (12.87%)  n=80/386 (20.73%) 
Parity  
Nulliparous n=41/266 (15.41%) n=45/386 (11.66%) 
0.16 (chi) Parous women 
N=564 (86.77%) 
n=224/266 (84.21%) n=340/386 (88.08%) 
* Depo Provera, COC, POP or Norethisterone  
 
The women who had HPV/CIN1 were older (37.14 years) than the women who had 
CIN2/CIN3 (36.15 years). This age difference is not clinically significant even though 
it is statistically significant. The time from Pap smear to colposcopy was longer 
(266.73 days) among women who had HPV/CIN1 compared with women who had 
CIN2/CIN3. Women who had HPV/CIN 1 had a longer duration of HIV infection (5.77 
years) and had a higher proportion of ART use (56.02% vs. 42.34%). The different 
contraceptive methods were analysed to determine the relationship between the 
different methods and the probability of having HPV/CIN1 or CIN 2/CIN3. The women 
who had HPV/CIN1 had a higher proportion of condom use compared to hormonal 
contraception as opposed to the women with CIN2/CIN3, their proportions were 
49.29% and 39.90% respectively. On the other hand the women with HPV/CIN1 had 
a lower proportion of hormonal contraception use compared to women with 
CIN2/CIN3, their proportions were 12.87% and 20.73% respectively. There was no 
statistical difference with respect to parity between these 2 groups of women.  
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Risk of CIN2 or more severe lesion in women with LSIL on Pap smear 
Table 3.6 below shows the unadjusted risk ratio of CIN2 or more severe lesion. The 
following variables, namely, duration of HIV infection, snuff usage, smoking, parity, 
age and time from Pap smear to presentation had no statistical significance of an 
increased risk of having CIN2 and more severe lesion. However, women who used 
hormonal contraception compared to women who used condoms were 2 times more 
likely to have CIN2 and more severe lesion. HIV infection was also significantly 
associated with having CIN 2 or more on histology. Women who used ART were 
43% less likely to have a more severe lesion and there was an approximately 20% 
less likely chance of having a more severe lesion with a higher CD4 count category.  
 
Table 3.6 Unadjusted risk ratio of CIN2 or more severe lesion 
 Unadjusted OR p-value 
Duration of HIV infection in weeks 1.00 0.20 
Time form Pap to colposcopy in days 0.998    0.00 
Use of snuff compared to no use 1.06 0.92 
Smoking compared to no smoking 1.13 0.89 
Parity 0.99    0.88 
Nulliparous compared to parous women 1.38 0.163 
Age (in years) 0.98 0.10      
ART use compared to no use 0.57    0.00 
CD4 count 0.99 0.00 
CD4 category compared to <200  cells/mm
3
  
≥200 0.81 0.00 
 
Hormonal contraception compared to condoms 2.00    0.003      
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CHAPTER 4 
 
4.1    Discussion 
The objectives of this study were to describe the characteristics of HIV infected 
women with LSIL on Pap smear, compare the characteristics of women with 
CIN 1 on histology with those who have CIN 2 or more on histology, compare 
the colposcopy findings to the histology results and finally to describe the 
proportion of women who have been overcalled at colposcopy and the 
proportion of women who were undercalled at colposcopy.  In this chapter, the 
results, limitations and strengths of the study will be discussed, followed by a 
conclusion and recommendations.  
 
In our study we found that about 59.20% of patients with LSIL on Pap smear had 
clinically significant disease on histology. This finding is much higher than in a study 
done by Soto-Wright V, Samuelson R, McLellan R et al where they found that 9%-
16% of patients with LSIL on Pap smear subsequently had CIN2 to CIN3 on 
biopsy.(40)   A South African study by Lindeque also found that about 15–30% of 
women with LSIL on cytology were expected to have CIN 2 or 3 on biopsy.(41) The 
IQR from when the Pap smear was performed and the first colposcopy visit was 
132.00 – 313.00 days, therefore a repeat Pap smear was not indicated in 75% of  
patients in our study. It is not our practice to repeat Pap smears even in women who 
arrive after a year of having had a Pap smear as this would further delay the 
colposcopic assessment. We can only postulate that in less than 25% of patients a 
repeat pap smear may have shown persistence, or progression. There were no 
patients with normal histology in this study.  
 
In a study done by Omar T, Schwartz S, Hanrahan C et al, also in a Soweto 
population they found that in HIV positive women with LSIL on baseline smear, there 
was a 0.8% progression rate to ASC-H and 21.5% to HSIL at five months repeat 
smear.(10) In contrast, though, a study done by Saayman F, van Gelderen C J, 
Michelow P et al showed that there was no significant increased risk of up or down-
grading of dysplasia with an interval of 6 months or more than 6 months between a 
Pap smear and histology. They also found that the use of ART had no effect on the risk of 
invasive disease or the upgrading of dysplasia. (11) 
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We also found that there were 5 women (0.77%) that had invasion on histology. This 
finding is slightly higher than in other studies that showed that up to 0.5% of patients 
with LSIL on Pap smear will have invasive cancer.(42) However, in these studies there 
were no HIV positive patients. The difference in this group of 5 women was not 
tested against the study population because of the small numbers. Only 1 out of 5 
women were on ART as the threshold for ART use was higher at the time of this 
study. These are important findings as they help us keep in mind that we do not 
understand the natural history of CIN  in HIV  positive women. It may be that 
progression is sooner in HIV positive women. A study done at the Charlotte Maxheke 
Johannesburg Academic hospital showed that HIV infected women presented with 
cervical cancer 10 years earlier than HIV negative women.(17) These findings support 
the ongoing practice that HIV positive women should be referred to colposcopy as 
soon as they have LSIL on their Pap smears. 
 
The mean age in our study was 36 years and this is similar to the peak age for 
development of cervical precursor lesions. The age and parity, in our study, were not 
associated with a more severe CIN lesion and this was also a finding in the study 
done by Omar T, Schwartz S, Hanrahan C et al.(10)   
 
In our study, 32.53% of women had a CD4 count less than 200 cells/mm3. This is 
less than the finding in Firnhaber‟s study where they found 42% of women (both LSIL 
and HSIL) in their study had a CD4 count of <200 cells/mm3.(16) In our study the 
mean CD4 count was low at 275.00 cells/mm3 and this is consistent with the known 
association of a low CD4 count with cervical dysplasia. Furthermore, the prevalence 
and degree of dysplasia increases with advancing levels of immunosuppression.(24) A 
low CD 4 count of ≤200 cells/mm3 proved to be a significant risk factor for severe 
disease in both our study and Firnhaber‟s study.(16) This fact was also true for 
progression to higher grade lesions in Omar‟s study.(10)   Finhaber C, Van Le H, 
Pettifor A et al also showed that women with CD4 counts <200 cells/mm3 had a 
higher prevalence of HPV 16 as well as high grade lesions.(16) In a study done by 
Clark, progression of LSIL to HSIL was associated with lower CD4 counts and 
presence of HPV types 16, 18, and 33 (5). Regrettably in our study we did not have 
information regarding HPV subtypes as HPV testing was not specifically performed.  
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Due to our study being retrospective and that viral load testing was not standard of 
care at the time of the study, we were unable to obtain information on viral load. We 
were also unable to determine the duration of ART usage and whether the duration 
had a protective effect against the risk of having CIN 2 or more severe lesions. Of 
importance, though, is that there was a higher percentage of women using ART in 
our study than in previous studies of HIV in SA, which is promising.  
 
Condom use was high at 43.17% and this was associated with a lower risk of CIN2 
or more severe lesions in our study and this finding was consistent with the results in 
Firnhaber‟s study. Condom usage was much higher in Firnhaber‟s study, with a 
reported 75.4% condom usage, however, their study was consistent with our study in 
that they also found condom use was associated with a lower risk of HSIL compared 
to non-condom users.(16) It is interesting and encouraging that condoms are a 
common contraceptive method in our study population. This might be because 
women that are HIV positive are more likely to use condoms when they know their 
status and/or clinics are promoting condom use to patients.  
 
Hormonal contraceptive use, specifically combined oral contraceptives (COC), has 
been associated with an increased risk of cervical cancer or upgrade of dysplasia in 
women infected with HPV.(4) In our study we found that women that used hormonal 
contraceptives were 2 times more likely than women who used condoms to have 
CIN2 and more severe lesion.  
 
Intuitively, one would have expected that the progression of CIN would be higher in 
HIV patients and in patients with a longer duration of HIV infection. However, HIV 
duration was not associated with a statistically significant increased risk of having a 
more severe cervical lesion. This could possibly be attributed to patients seeking HIV 
treatment earlier. 
 
The colposcopy clinic at CHBAH uses a “see-and-treat” policy in order to avoid loss 
of patient follow-up. The disadvantage of this management policy is that patients may 
be exposed to overtreatment. As a result, patients with a lower-grade lesion or with a 
normal cervix may receive inappropriate and excessive treatment, and they may be 
exposed to bleeding and infection unnecessarily.(39)  
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Overtreatment can be defined based on either a conservative or a more aggressive 
approach to the treatment of squamous intraepithelial lesions. In a conservative 
approach, the appropriate treatment threshold is defined as a diagnosis of high-grade 
SIL or worse. This approach states the numerator as the number of patients who 
were treated and found to have a normal or low-grade SIL at histology. As a result, 
this approach yields more patients who are overtreated at the time of the diagnostic 
visit. With a more aggressive approach, the appropriate treatment is when histology 
results show a low-grade SIL or worse. The numerator for overtreatment with this 
approach is the number of patients treated and found to have normal histological 
results and no SIL.(39) 
 
In our study we found that 129 women (21.83%) were over diagnosed and therefore 
overtreated – this is using CIN 2 and more severe lesion as a threshold for treatment.  
There is therefore a greater risk of overtreatment of HIV positive women with LSIL 
who are referred to a colposcopy clinic where immediate treatment is practiced. 
However colposcopy was better in predicting a clinically significant lesion when the 
colposcopic diagnosis was CIN3 or more. 
 
Punch biopsies may therefore be important in women with CIN 2 and less severe 
disease (on colposcopy) in order to reduce overtreatment. However punch biopsies 
have not been shown to be very accurate when compared to cone biopsies and 
LLETZ.(30) 
 
In a study done by Bigrigg MA, Codling BW, Pearson P et al, the reported 
overtreatment was 27.9% if the threshold was a pathology report of low-grade SIL 
and 4.7% if the pathology report was negative.(44)  In another study done by Keijser 
KG, Kenemans P, van der Zanden PH et al, patients diagnosed with any grade of 
CIN were treated and they reported overtreatment of 13.3% for low-grade SIL and of 
7.0% for a negative pathology report.(45)  Megevand E, Van Wyk W, Knight B et al 
had overtreatment of 21.8% in low-grade SIL or normal histology results.(46)   
However, these women were HIV negative. 
 
Histology was considered the „gold standard‟ diagnostic tool in our study and the 
threshold for treatment in our colposcopy clinic was considered to be CIN 2 since 
2006. Omar T, Schwartz S, Hanrahan C et al found that colposcopy had a sensitivity 
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of 54%-85% for the detection of CIN 3.(10) We found that 61 of the 591 women 
(10.49%) were underdiagnosed. This is concerning as the risk associated with  
underdiagnosis is that patients that don‟t return for their results can end up being lost 
to follow-up and thus risk progressing to cervical cancer.(39) 
 
In comparison to the other levels of cervical dysplasia, CIN1 had the highest rate of 
underdiagnosis. A possible reason to account for this difference could be that the 
colposcopists were influenced by prior knowledge that the patients had LSIL on their 
Pap smear and therefore expected a CIN1 diagnosis on colposcopy. This 
demonstrates the importance of adhering to the diagnostic protocols of colposcopy 
and therefore correct treatment for the patients.  
 
Colposcopy is not a reliable method of recognizing glandular disease or early 
invasive cancer. (29) Our study confirmed these findings as we found that colposcopy 
was an unreliable tool for diagnosing microinvasion (0.00%).  
 
 LLETZ is considered both a diagnostic and therapeutic procedure and it provides a 
conservative management approach to the treatment of HSIL. In some patients, 
however, cervical lesions persist or recur and positive margins have been identified 
as an important predictive factor. Having both margins positive carries the highest 
risk of recurrence as compared to one margin or no margins being positive.(43,47) 
Moreover, Zhu M, He Y, Baak JPA et al found in their study that the persistence rate 
of cervical lesions in patients with HSIL was 11.3%. They also found that women who 
were over 35 years of age were 4.6 times more likely to have persistence of or 
recurrence of cervical lesions.(48) In our study, 4.98% of women had involvement of 
both margins and 5.31% had involvement of the endocervical margins. In a study 
done by Kabir F, van Gelderen C, McIntyre J et al, using the same database as ours, 
they found involvement of both margins in 12.66%,(43) which is much higher than in 
our study. Possible reasons to account for this difference is that our study only 
looked at HIV positive patients with low grade SIL and the study by Kabir F, van 
Gelderen C, McIntyre J et al looked at HIV positive patients with both LSIL and HSIL. 
LSILs on Pap smear may be associated with smaller lesions and we had lower rates 
of both margin involvements compared to Kabir‟s study. High-risk HPV testing has 
been shown to be a useful predictor of recurrence, however, HPV testing was not 
done in our study.  
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4.2 Strengths 
The strength of our study is that all our patients had histology as a „gold standard‟ of 
diagnosis.  
 
4.3  Limitations 
 
This is a retrospective study and therefore missing information was not obtainable. 
Other variables for risk factors for carcinoma of the cervix have not been collected in 
the database, e.g. sexual history, coitarche and number of sexual partners. Smoking 
and use of snuff were only added in the database from 2010. 
 
Another limitation of this study is that it is a cross sectional study with a long interval 
between LSIL and colposcopy/biopsy. We were also not able to determine HPV 
subtypes in our study population because it is not standard of care.  HIV parameters 
change over time and we did not know how long these women were on ART, we also 
did not have information on their viral loads and we did not have serial CD4 counts. 
This database is a clinical database and missing information could not be obtained. 
 
4.4  Recommendations 
Recommendations for further research:  
A prospective study which may assist in finding factors that will increase the 
sensitivity and the specificity of colposcopy, thereby reducing the risks of both over 
and under treatment. 
 
Markers of HPV infection: 
A prospective study to determine the common HPV subtypes in our population would 
be beneficial and will add to our knowledge and understanding of LSIL in HIV positive 
patients. The knowledge of HPV subtyping may assist in the screening and prediction 
of patients who will progress to more severe lesions and those who will be at risk of 
persistence.  Palefsky JM, Minkoff H, Kalish LA et al found the prevalence of HPV in 
HIV positive women to be 20%-34%, resulting in these patients being about 5 times 
more likely to have high risk HPV infection than in HIV negative women.(49)  
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Clinical recommendations: 
Addressing the long waiting time between Pap smear and colposcopy will help in 
reducing the chances of women with LSIL progressing to more severe lesions by the 
time they present for colposcopy. 
 
Our recommendation is that women who are HIV positive should still be referred to 
colposcopy. In this study we found 5 women with invasive cervical cancer and 
previously, from the same population, in a study done by Saayman F, van Gelderen 
C J, Michelow P et al, this number was 4 women.(11) South Africa has one of the 
highest HIV prevalence rates in the world. HIV positive women are living relatively 
long lives because of improved access to ART and consequently at a higher risk of 
progression from CIN 2/3 to invasive cervical cancer.(28) It is therefore imperative that 
HIV positive women with LSIL be promptly managed to avoid the progression to 
cervical cancer. Starting ART earlier and continuing with the ART that was started 
during pregnancy will assist in improving patient‟s health and therefore reducing 
disease progression. 
 
It is important that there is ongoing quality control in colposcopy.  Using a uniform 
scoring system for all colposcopists may reduce the chances of over and under 
diagnosis, thereby ensuring that patients are properly diagnosed and appropriately 
treated.  
 
4.4 Conclusion  
We found that HIV infected women with LSIL on Pap smear had a high frequency of 
clinically significant cervical disease (n=386 [59.20%]). At CHBAH colposcopy clinic 
we use a threshold for treatment of CIN 2 at colposcopy. From this study it is evident 
that using a threshold for treatment of CIN3 in women with a Pap smear report of 
LSIL will lead to  an overtreatment of 12/91 (13.91%) and using a threshold of CIN 2 
for treatment at colposcopy would result in an overtreatment of 30.86%.  
 
We would recommend that for women with LSIL on Pap smear and a colposcopy 
finding of CIN 1, treatment should be based on histology obtained by a punch biopsy. 
For women with CIN 2 on colposcopy treatment with immediate LLETZ should be 
individualized according to adequacy of the colposcopy, age of the patient and desire 
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for pregnancy. In cases where the colposcopy is a CIN 3, a LLETZ may be 
performed immediately in this setting.   
 
The long time interval between the Pap smear and the colposcopy visit is a concern 
that needs to be addressed by the Department of Health. The fact that we found five 
women with invasive disease in this group is a concern, although we are uncertain 
whether these women were candidates for a biopsy at the time that they had the pap 
smear. The South African guidelines state that HIV positive women with any 
abnormality should be referred to colposcopy. Cytology services in the Public Health 
sector have also not been able to produce reports with results within four weeks. 
There is a long waiting time for colposcopy. (personal communication) 
 
We found a significant association of low CD4 (<200 cells/mm3) with a clinically 
significant lesion of CIN2 and more severe. The use of ART was associated with a 
lower frequency of a clinically significant lesion.  This study therefore further 
emphasizes the need for ART at diagnosis of HIV infection. 
.  
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Appendix F 
 
Modified Reid colposcopic index 
Feature 0 points 1 point 2 points 
Colour of 
acetowhite 
(AW) area 
Low-intensity 
acetowhitening; snow-
white, shiny AW; 
indistinct AW; 
transparent AW;  
AW beyond the 
transformation zone 
Grey-white AW with 
shiny surface 
 
Dull, oyster-white; 
Grey 
 
AW lesion margin 
and surface 
configuration 
Feathered margins; 
angular, jagged 
lesions; flat lesions 
with indistinct margins; 
microcondylomatous 
or micropapillary 
surface 
Regular lesions with 
smooth,  straight 
outlines 
 
Rolled, peeling edges; 
internal demarcations 
(a central area of 
highgrade change 
and peripheral area of 
lowgrade change) 
 
Vessels Fine/uniform vessels; 
poorly formed patterns 
of fine punctuations 
and/or fine mosaic; 
vessels beyond the 
margin of 
transformation zone; 
fine vessels within 
microcondylomatous 
or micropapillary 
lesions 
Absent vessels 
 
Well defined coarse 
punctation or coarse 
mosaic 
Iodine staining Positive iodine uptake 
giving mahogany 
brown colour; negative 
uptake of lesions 
scoring 3 points or less 
on above three 
categories 
Partial iodine up-
take by a lesion 
scoring 4 or more 
points on above 
three categories – 
variegated, speckled 
appearance 
Negative iodine 
uptake 
by a lesion scoring 4 
or more points on the 
above three criteria 
 
Adapted from Coppleson et al., 1993 b(50) 
Scoring: A score of 0 to 2 points = Likely to be CIN 1; 3-4 points = Overlapping lesion: likely 
to be CIN 1 - 2; 5 to 8 points = Likely to be CIN 2 - 3 lesions. 
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Appendix G 
 
DATA SHEET 
The following variables will be extracted from the colposcopy database: 
Age  
Parity 
Current Contraception: 
Type of contraception (tick the relevant type) 
COC  
Condoms  
DMPA  
Nur-Isterate (Nurethisterone enantate)  
Progestogen only pill  
IUCD  
Sterilisation  
None   
Other   
 
CD4 count (within 6 months)   
ART use       
 
Colposcopy diagnosis as recorded in the database  
Type of biopsy  Punch biopsy 
   LLETZ 
   Cone biopsy 
   Hysterectomy (if performed)  
N  
Y 
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Histology results Normal 
   HPV only 
   Cervicitis only 
   CIN 1 
   CIN 2 
   CIN 3  
   Microinvasion 
   Invasion 
   Other 
 
 
 
 
 
 
 
 
 
 
